It's not just the an­ti­bod­ies: Eli Lil­ly bur­nish­es its sec­ond EUA in play with new Covid-19 da­ta on Olu­mi­ant plus remde­sivir

Eli Lil­ly is on a roll.

Days af­ter re­port­ing pos­i­tive da­ta for its Covid-19 neu­tral­iz­ing an­ti­bod­ies, the phar­ma gi­ant said adding its JAK in­hibitor Olu­mi­ant to Gilead’s remde­sivir cut the risk of death — al­though the re­sult wasn’t sta­tis­ti­cal­ly sig­nif­i­cant.

New da­ta from ACTT-2, an adop­tive treat­ment tri­al con­duct­ed by the NIH, are in line with what in­ves­ti­ga­tors dis­closed a month ago re­gard­ing im­prove­ments in time to re­cov­ery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER